Glassia approved for treating alpha 1 antitrypsin deficiency

Kamada announced that the FDA has approved Glassia (alpha1-proteinase inhibitor liquid) for chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (AATD). Glassia is a high purity, ready-to-use liquid alpha1-proteinase inhibitor.

For more information call (866) GLASSIA or visit www.myglassia.com.